Related Experiment Video

Updated: Aug 25, 2026

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

Cytochrome P450 enzymes: novel options for cancer therapeutics

Morag C E McFadyen1, William T Melvin, Graeme I Murray

  • 1Department of Pathology, University of Aberdeen, Aberdeen, United Kingdom. m.mcfadyen@abdn.ac.uk

Molecular Cancer Therapeutics
|March 18, 2004
PubMed

Insights

Overexpression of cytochrome P450 enzymes, especially CYP1B1, in tumor cells offers new anticancer therapy targets. This review explores therapeutic strategies using enhanced P450 expression and gene therapy for cancer treatment.

Area of Science:

  • Biochemistry and Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • Cytochrome P450 (P450) enzymes are increasingly recognized for their overexpression in tumor cells.
  • Specific P450s, notably CYP1B1, are identified as promising targets for novel anticancer therapies.

Purpose of the Study:

  • To review emerging therapeutic options for cancer treatment.
  • To explore opportunities presented by enhanced endogenous cytochrome P450 expression in tumors.
  • To discuss the potential of cytochrome P450-mediated gene therapy.

Main Methods:

  • Literature review of recent research on P450 enzymes in cancer.
  • Analysis of studies focusing on CYP1B1 overexpression in neoplastic tissues.
  • Examination of therapeutic strategies involving P450-based gene therapy.

Main Results:

  • Evidence supports P450 overexpression, particularly CYP1B1, as a hallmark of various cancers.
  • Enhanced P450 activity in tumors can be leveraged for targeted drug activation or prodrug strategies.
  • P450-mediated gene therapy presents a novel approach for selective tumor cell killing.

Conclusions:

  • Targeting P450 enzymes, especially CYP1B1, in tumors offers significant potential for developing innovative anticancer treatments.
  • Exploiting both endogenous P450 overexpression and P450-mediated gene therapy can lead to more effective and selective cancer therapies.

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...